Atorvastatin treatment in Systemic Lupus Erythematosus patients

Influence of Atorvastatin on coronary calcifications and myocardial perfusion defects in Systemic Lupus Erythematosus patients: a prospective, randomised, double-masked, placebo-controlled study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN51612701

Enrollment

Registered

2011-02-18

Start date

2006-01-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic lupus erythematosus Musculoskeletal Diseases Systemic lupus erythematosus

Interventions

Atorvastatin treatment (40 mg/day) versus placebo. Total duration of treatment: 1 year. One year follow-up period.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients aged 20 - 73, either sex 2. Fulfilled at least 4 American College of Rheumatology (ACR) classification criteria for SLE 3. In stable clinical conditions (no need for immunosuppressive therapy intensification, i.e. current immunosuppressive drug dose increase or introduction of an additional immunosuppressive drug within last 3 months)

Exclusion criteria

Exclusion criteria: 1. Known cancer 2. Clinical symptoms of coronary heart disease or heart failure (New York Heart Association [NYHA] III or IV class) 3. Renal failure (creatinine clearance less than 30 ml/min) 4. Respiratory failure

Design outcomes

Primary

Measure	Time frame
Measured at 0 and 12 months: 1. Calcium deposits in coronary arteries 2. Number of myocardial left ventricle segments with perfusion defects	—

Secondary

Measure	Time frame
Measured at 0, 3, 6, 12 months: 1. Symptoms of myocardial ischaemia 2. Need for reperfusion therapy 3. Deaths	—

Countries

Poland

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026